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We thank the reviewer for evaluating and commenting on our manuscript. 1. Grammatical adjustments were made according to the suggestions. 2. The JNC-7 description was deleted. 3. In the first paragraph of the discussion, the main findings were added. 4. The relation between masked hypertension and smoking was added, as a hypothesis of the findings related to hypertension in our study.

Introduction
============

Smoking is one the main causes of morbidity and mortality in the working-age population; it is responsible for approximately 7.2 million deaths per year ^[@ref-1]^. This constitutes a major public health issue. Almost one-third of the world population older than 15 years of age smokes ^[@ref-2]^, with a global prevalence of 21.2% in developing countries ^[@ref-3]^. In the Americas, the prevalence in the general adult population is 17.1% ^[@ref-4]^; however, this varies among different countries, with Chile having the highest (38.9%) and Panama the lowest (7.4%) rates ^[@ref-4]^. Venezuela is a country with one of the highest prevalence (33.9%) ^[@ref-5]^, with a frequency of 14.8% in Maracaibo City in recent studies ^[@ref-6]^.

Smoking habit is a major modifiable risk factor for developing non-communicable diseases ^[@ref-2]^, including cardiovascular disease (CVD) and type 2 diabetes mellitus (DM2) ^[@ref-7]^. A growing body of evidence suggests that before the onset of these two diseases, cigarette smoking favors the appearance of metabolic syndrome (MS) ^[@ref-8],\ [@ref-9]^ high blood pressure, dyslipidemia, obesity and high blood glucose ^[@ref-10]--\ [@ref-14]^. Main contributors for this association include the presence of dyslipidemia and central obesity ^[@ref-15]^.

The physiopathology of the relationship between cigarette smoking and MS comes from a decrease in peripheral insulin sensitivity, lipoproteins metabolism alterations and endothelial dysfunction, all present in smoking individuals ^[@ref-16]^. Until now, epidemiological published results are not definitive in showing the association between cigarette smoking and MS. On the other hand, it is not certain whether this association is caused by other behavioral patterns and unhealthy habits of patients with cardiometabolic diseases ^[@ref-17]^. Thus, the aim of this study was to evaluate the relationship between smoking habit and MS components in the adult population from Maracaibo City, Venezuela.

Methods
=======

Study design and subject selection
----------------------------------

The Maracaibo city MS prevalence study (MMSPS) was a cross-sectional, descriptive study performed in Maracaibo, Venezuela. It was designed to provide estimations about the presence of MS and associated cardiovascular risk factors in the adult population during the period between May 2007 and December 2009. The study method was reported previously ^[@ref-18]^. The most important aspects of the protocol are presented here. Maracaibo city was divided into parishes, which were sampled proportionally through a multistage random sampling, defining conglomerates in two phases: In the first phase, the conglomerates represented the sectors of the 18 parishes, selecting 4 areas per parish by means of simple random sampling; in the second phase, the conglomerates were represented by the neighborhood of each chosen area, to which a random number was assigned. To evaluate smoking habit in this sub-study, 18 subjects were excluded: 9 because of inconsistencies about when they started smoking; the other 9 subjects because they smoked cigar types that were different to cigarettes. Finally, a total of 2212 subjects were evaluated. The study was approved by the Bioethics Committee of the Endocrine and Metabolic Research Center -- University of Zulia (approval number: BEC-006-0305). This ethical approval included all future studies that used the data from the MMSPS. All participants signed an informed consent form before being questioned and physically examined by a trained team.

Clinical evaluation
-------------------

Every subject in the study underwent a medical examination performed by trained personnel to obtain a full medical history. During the anamnesis, past medical and family history of endocrine and metabolic disorders was collected; including age, race, marriage status, education and socioeconomic status. The latter was measured using the Graffar scale modified by Mendez-Castellano and De Mendez ^[@ref-19]^.

The auscultatory method was performed to measure arterial pressure, using an adequate calibrated and validated sphygmomanometer. Korotkoff phases I and V were used to measure systolic and diastolic pressures, respectively. Subjects remained sitting still for 15 minutes before assessment, with both feet on the ground. A total of 3 measurements per day were taken in 15 minute intervals, for 2 days consecutively. Anthropometric measures were taken using a height rod that had been previously calibrated and placed on a flat surface. Weight was measured using a digital weighing scale (Tanita, TBF-310 GS Body Composition Analyzer; Tokyo, Japan), with the patient wearing light clothes and no shoes. The body mass index (BMI) was calculated applying the Quetelec formula (weight/height ^2^), and classified according to the WHO classification ^[@ref-20]^, as follows: normal weight (\<25 Kg/m ^2^), overweight (25.0--29.9 Kg/m ^2^), obese (≥30.0 Kg/m ^2^). Abdominal circumference was measured using a plastic measuring tape, graded in centimeters and millimeters, in a spot equidistant to the lower ribcage and the anterior-superior iliac spine, according to the United States National Institute of Health protocol ^[@ref-21]^.

Smoking habit evaluation
------------------------

Subjects were asked about smoking habit presence and duration, being categorized as: a) current smoker, any subject who had smoked more than 100 cigarettes in his/her lifetime, is currently smoking, or less than 1 year had passed after he/she quit smoking; b) Former smoker: any subject who has quit smoking for more than 1 year; c) non-smoker, any subject who has never smoked or had smoked less than 100 cigarettes in his/her lifetime ^[@ref-6]^. Smoking intensity was assessed posteriorly, according to number of cigarettes per day. It was divided in the following tertiles: T1 \<3 cigarettes/day; T2 = 3--9 cigarettes/day; and T3 ≥10 cigarettes/day.

Physical activity and alcohol consumption evaluations
-----------------------------------------------------

Physical activity was evaluated using the International Physical Activity Questionnaire ^[@ref-22]^. It takes into account four elements of evaluation: physical activity in transport, work, domestic and gardening, and leisure time. To quantify time investment on each element, subjects were classified in quintiles. The final scoring was reported using metabolic equivalents (METs)-min/week on each item; any subject with 0 METs was considered as physically inactive.

Subjects with ≥1 MET were classified in quintiles according to gender, resulting in six categories for physical activity: physical inactivity (MET = 0), very low (Q1), low (Q2), moderate (Q3), high (Q4), and very high (Q5) physical activity. Leisure time was classified as: a) Q1 or very low physical activity, \<296.999 METs for men and \<230.999 METs for women; b) Q2 or low physical activity, 297.000--791.999 METs for men and 231.000-445.499 METs for women; Q3 or moderate physical activity, 792.000--1532.399 METs for men and 445.500-742.499 METs for women; Q4 or high physical activity, 1532.400--2879.999 MET for men and 742,500--1798.499 METs for women; and e) Q5 or very high physical activity, ≥2879.000 METs for men and ≥1798.500 METs for women. For alcohol consumption, any subject that drinks ≥1 gram daily was considered as a "drinker" ^[@ref-23]^.

Laboratory analysis
-------------------

After 8 hours of fasting, a blood sample was taken from the cubital vein, and was centrifuged to obtain the serum. Serum levels of glucose (catalog number REF-10123), total cholesterol (catalog number REF-10015) and triacylglycerides (TAG) (catalog number REF-10163) were determined using enzymatic--colorimetric kits (Human Gesellschaft für Biochemica und Diagnostica mbH) and a specialized computer system. Glycemic status was classified according to ADA 2017 criteria in normal glucose (basal glucose, \<100 mg/dl), impaired fasting glucose (basal glucose, 100--125 mg/dl) and DM2 (≥126 mg/dl) ^[@ref-24]^. Serum hs-C reactive protein (hs-CRP) levels were quantified using immunoturbodimetric assays (Human Gesellschaft für Biochemica und Diagnostica mbH. (catalog number REF-11544), setting the cutoff point at ≥0,765 mg/l ^[@ref-25]^.

Basal insulin serum levels were determined using a commercial kit (catalog number EIA-2935) based on the ELISA method (DRG International, Inc.), with a detection limit of \<1 mU/l. Insulin resistance (IR) was calculated using software ( [HOMA-Calculator v2.2.2](http://www.dtu.ox.ac.uk/homacalculator/index.php)) supplied by the Oxford Centre for Diabetes, Endocrinology and Metabolism; the cutoff-point for HOMA2-IR was 2.00 ^[@ref-26]^.

Metabolic syndrome evaluation
-----------------------------

MS diagnosis was made using the proposed criteria from the IDF and AHA/NHLBI in 2009 ^[@ref-27]^. It requires three or more of the following components to achieve a diagnosis: 1) TAG ≥150 mg/dl; 2) high-density lipoprotein--cholesterol (HDL-C) \<40 mg/dl for men or \<50 mg/dl for women; 3) basal glucose levels ≥100 mg/dl, or a previous diagnosis of DM2 or use of an antidiabetic drug; 4) arterial pressure ≥130/85 mmHg, or a previous diagnosis of hypertension or use of an antihypertensive drug; 5) abdominal circumference with cutoff points adapted for our population, which are ≥91 for women and ≥98 cm for men ^[@ref-28]^.

Statistical analysis
--------------------

Qualitative variables were expressed in absolute and relative frequencies. The relationship between these was examined with a χ ^2^test and the difference in proportions using a Z-test. Quantitative variables were expressed in arithmetic means ± standard deviations, with prior analysis using Geary's test. Variables without a normal distribution were submitted to logarithmic transformation with posterior normality test. Multiple logistic regression models were made to estimate odds ratios (OR) and 95% confidence intervals (95% CI); they were used for the presence of MS and each of its components, adjusted for gender, age, ethnic group, marital status, education level, socioeconomic status, working status, alcohol consumption, BMI categories, insulin resistance and smoking habit. On another model, smoking intensity was assessed dividing consumption in tertiles (T1 \<3 cigarettes/day; T2 = 3--9 cigarettes/day; and T3 ≥10 cigarettes/day). Data were analyzed by using SPSS v.21 for Windows (IBM SPSS), and considering statistically significant results when *p*\<0,05.

Results
=======

General characteristics of the sample
-------------------------------------

A total of 2212 individuals were studied, of whom 52.7% (n=1166) were women. The mean age ± SD was 39.27±15.38 years, and the most frequently occurring age group was 30--49 years (38.5%; n=851). For smoking habit, 14.8% were smokers (n=328), 15.4% former smokers (n=340) and 69.8% were non-smokers (n=1544). The prevalence of MS was 35.7% (n=935) in the sample. The most frequent MS components were low HDL-C (57.6%; n=1275) and abdominal obesity (48.5%; n=1072). Other general characteristics can be found in [Table 1](#T1){ref-type="table"}.

###### General characteristics of the sample population.

  -------------------------------------------------------------------------------------------------------
  Variable                                          Female\    Male\      Total\                   
                                                    (n=1166)   (n=1046)   (n=2212)                 
  ------------------------------------------------- ---------- ---------- ---------- ------ ------ ------
  Age (years)                                                                                      

  \<30                                              349        29.9       410        39.2   759    34.3

  30--49                                            464        39.8       387        37.0   851    38.5

  ≥50                                               353        30.3       249        23.8   602    27.2

  Marital status                                                                                   

    Single                                          495        42.5       455        43.5   950    42.9

    Married                                         427        36.6       446        42.6   873    39.5

    Other                                           244        20.9       145        13.9   389    17.6

  Socioeconomic status                                                                             

    Stratus I: high class                           17         1.5        19         1.8    36     1.6

    Stratus II: middle-high class                   206        17.7       204        19.5   410    18.5

    Stratus III: middle class                       432        37.0       440        42.1   872    39.4

    Stratus IV: Working class                       446        38.3       344        32.9   790    35.7

    Stratus V: extreme poverty                      65         5.6        39         3.7    104    4.7

  Working status                                                                                   

    Employed                                        527        45.2       757        72.4   1284   58.0

    Unemployed                                      639        54.8       289        27.6   928    42.0

  Education                                                                                        

    Illiterate                                      33         2.8        19         1.8    52     2.4

    Primary school                                  237        20.3       112        10.7   349    15.8

    High school                                     516        44.3       519        49.6   1035   46.8

    Higher education                                380        32.6       396        37.9   776    35.1

  Ethnic group                                                                                     

    Mixed                                           873        74.9       807        77.2   1680   75.9

    White-Hispanic                                  189        16.2       159        15.2   348    15.7

    Afro-Venezuelan                                 30         2.6        36         3.4    66     3.0

    Indigenous American                             62         5.3        43         4.1    105    4.7

    Other                                           12         1.0        1          0.1    13     0.6

  Smoking habit                                                                                    

    Non smoker                                      878        75.3       666        63.7   1544   69.8

    Current smoker                                  134        11.5       194        18.5   328    14.8

    Former smoker                                   154        13.2       186        17.8   340    15.4

  Leisure time physical activity                                                                   

    Inactive                                        832        71.4       529        50.9   1361   61.7

    Very low                                        67         5.7        99         9.5    166    7.5

    Low                                             62         5.3        102        9.8    164    7.4

    Moderate                                        64         5.5        103        9.9    167    7.6

    High                                            72         6.2        92         8.8    164    7.4

    Very high                                       69         5.9        115        11.1   184    8.3

  Alcohol consumption                               219        18.8       505        48.3   724    32.7

  Metabolic syndrome [†](#FN1){ref-type="other"}    470        40.3       465        44.5   935    42.3

  Metabolic syndrome [‡](#FN1){ref-type="other"}    391        33.5       398        38.0   789    35.7

  Low HDL [†](#FN1){ref-type="other"}               747        64.1       528        50.5   1275   57.6

  High TAG [†](#FN1){ref-type="other"}              268        23.0       343        32.8   611    27.6

  Hyperglycemia [†](#FN1){ref-type="other"}         301        25.8       317        30.3   618    27.9

  High blood pressure [†](#FN1){ref-type="other"}   406        34.8       447        42.7   853    38.6

  Abdominal obesity [†](#FN1){ref-type="other"}     920        78.9       741        70.8   1661   75.1

  Abdominal obesity [‡](#FN1){ref-type="other"}     569        48.8       503        48.1   1072   48.5
  -------------------------------------------------------------------------------------------------------

WC, waist circumference; HDL, high-density lipoprotein; TAG, triacylglycerides. †According to IDF and AHA/NHLBI-ISO-2009 Consensus ^[@ref-27]^. ‡ According to The Maracaibo City Metabolic Syndrome Study ^[@ref-28]^: WC ≥98cm for men; ≥91cm for women.

Smoking habit and metabolic syndrome components
-----------------------------------------------

Smoking habit in accordance to MS components could be seen in [Table 2](#T2){ref-type="table"}. It shows a statistically significant association between cigarette smoking and having MS (χ ^2^=39.285; *p\<*0.001) with a greater percentage of individuals with MS in former smokers (47.9%) and current smokers (42.1%) than in non-smokers (31.6%), *p*\<0.05.

###### Smoking habit in accordance with MS and its components.

Maracaibo, Venezuela.

  Smoking status   MS [‡](#FN2){ref-type="other"}   High TAG [†](#FN2){ref-type="other"}   Abdominal obesity [‡](#FN2){ref-type="other"}   Hyperglycemia [†](#FN2){ref-type="other"}   Low HDL-C [†](#FN2){ref-type="other"}   High BP [†](#FN2){ref-type="other"}                                   
  ---------------- -------------------------------- -------------------------------------- ----------------------------------------------- ------------------------------------------- --------------------------------------- ------------------------------------- ----- ------ ----- ------ ----- ------
  Nonsmoker        488                              31.6                                   364                                             23.6                                        687                                     44.5                                  400   25.9   878   56.9   569   36.9
  Current Smoker   138                              42.1                                   121                                             36.9                                        171                                     52.1                                  104   31.7   201   61.3   119   36.3
  Former Smoker    163                              47.9                                   126                                             37.1                                        214                                     62.9                                  114   33.5   196   57.6   165   48.5

MS, Metabolic Syndrome; TAG, triacylglycerides; HDL-C, high-density lipoprotein-cholesterol; BP, blood pressure.

MS: χ ^2^ *=* 39.285 (p\<0.001); High TAG: χ ^2^ *=* 41.886 (p\<0.001); Abdominal Obesity: χ ^2^ *=* 40.039 (p\<0.001); Hyperglycemia: χ ^2^ *=* 10.759 (p=0.005); Low HDL-C levels: χ ^2^ *=* 2.160 (p=0.340); High Blood Pressure: χ ^2^ *=* 16.883 (p\<0.001). †According to IDF and AHA-NHLBI-ISO 2009 ^[@ref-27]^. ‡ According to The Maracaibo City Metabolic Syndrome Study ^[@ref-28]^: WC ≥98cm for men; ≥91cm for women.

Each component of the MS was analyzed in relation to smoking. A higher percentage of individuals with high TAG were former (37.1%) and current (36.9%) smokers, compared with non-smokers (23.6%) (χ ^2^=41.886; *p*\<0.001). The same happened for abdominal obesity in former smokers (62.9%) and current smokers (52.1%) (χ ^2^=40.039, *p*\<0.001). A high percentage of former smokers presented hyperglycemia (33.5% vs 25.9%; χ ^2^=10.759; *p*\<0.005) and high blood pressure (48.5 vs 36.9%; χ ^2^=16.88; *p*\<0.001) in comparison to nonsmokers. No statistical association was found between low HDL-C and smoking status.

Comparing smoking habit with the number of MS criteria ( [Figure 1](#f1){ref-type="fig"}), a statistically significant association was observed (χ ^2^=49.249, *p*\<0.001). The highest percentages were with nonsmokers who met 0 criteria (76.31%) and 1 criterion (76.77%). However, the greatest prevalence of smokers was observed in subjects who met 4 (16.96%) and 5 (20%) criteria.

![Smoking habit and number of metabolic syndrome criteria in subjects from Maracaibo, Venezuela.](f1000research-7-19517-g0000){#f1}

Smoking habit as a risk factor for MS and its components
--------------------------------------------------------

In [Table 3](#T3){ref-type="table"}, models of multivariate logistic regression are shown for the diagnosis of MS and its components. An association between current smoking and increased risk of presenting with MS could be observed (OR, 1.54; 95% CI, 1.11--2.14; *p*=0.010); the same was true of high TAG serum levels (OR, 1.66; 95% CI, 1.23--2.23; *p\<*0.001); abdominal obesity (OR, 1.54; 95% CI, 1.05--2.28; *p=*0.027) and low HDL-C levels (OR, 1.32; 95% CI, 1.01--1.74; *p*=0.046).

###### Adjusted OR for metabolic syndrome and its components according to smoking habit in Maracaibo, Venezuela.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Smoking\   MS [‡](#tfn3){ref-type="other"}   High TAG [†](#tfn3){ref-type="other"}   Abdominal\                             Hyperglycemia [†](#tfn3){ref-type="other"}   Low HDL-C [†](#tfn3){ref-type="other"}   High BP [†](#tfn3){ref-type="other"}
  status                                                                               Obesity [‡](#tfn3){ref-type="other"}                                                                                         
  ---------- --------------------------------- --------------------------------------- -------------------------------------- -------------------------------------------- ---------------------------------------- --------------------------------------
  Non-\      1.00                              1.00                                    1.00                                   1.00                                         1.00                                     1.00
  smokers                                                                                                                                                                                                           

  Current\   1.54 (1.11--2.14);\               1.66 (1.23--2.23);\                     1.54 (1.05--2.28);\                    1.13 (0.83--1.54);\                          1.32 (1.01--1.74);\                      0.70 (0.51--0.95);\
  smokers    0.010                             \<0.001                                 0.027                                  0.408                                        0.046                                    0.025

  Former\    0.96 (0.70--1.31);\               1.15 (0.86--1.53);\                     1.24 (0.85--1.81);\                    0.86 (0.64--1.16);\                          0.97 (0.74--1.26);\                      0.79 (0.58--1.06);\
  smokers    0.799                             0.324                                   0.245                                  0.330                                        0.832                                    0.127
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TAG, triacylglycerides; HDL-C, high-density lipoprotein-cholesterol; BP, blood pressure; OR, odds ratio; CI, confidence interval. †According to IDF and AHA/NHLBI-ISO 2009 ^[@ref-27]^. ‡ According to The Maracaibo City Metabolic Syndrome Study ^[@ref-28]^: WC ≥98cm for men; ≥91cm for women.

On the other hand, by assessing smoking intensity according to number of cigarettes per day ( [Table 4](#T4){ref-type="table"}), an association between the consumption tertile and high serum TAG levels was observed (T3: OR, 1.51; 95% CI, 1.03--2.22; *p=*0.036). Also, an association was observed between smoking intensity and abdominal obesity (T3: OR, 2.05; 95% CI, 1.15--3.64; *p=*0.015). By contrast, an inverse relationship was observed with high blood pressure (T3: OR, 0.66; 95% CI, 0.44--0.99; *p=*0.045).

###### Adjusted odds ratios for MS and its components according to smoking habit intensity in Maracaibo, Venezuela.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Smoking status        MS [‡](#tfn4){ref-type="other"}   High TAG [†](#tfn4){ref-type="other"}   Abdominal\                             Hyperglycemia [†](#tfn4){ref-type="other"}   Low HDL-C [†](#tfn4){ref-type="other"}   High BP [†](#tfn4){ref-type="other"}
                                                                                                  Obesity [‡](#tfn4){ref-type="other"}                                                                                         
  --------------------- --------------------------------- --------------------------------------- -------------------------------------- -------------------------------------------- ---------------------------------------- --------------------------------------
  Non-smoker            1.00                              1.00                                    1.00                                   1.00                                         1.00                                     1.00

  \<3 cigarettes/day    1.13 (0.79--1.62);\               1.25 (0.90--1.73);\                     1.42 (0.94--2.13);\                    1.02 (0.72--1.42);\                          1.10 (0.82--1.47);\                      0.75 (0.54--1.06);\
                        0.487                             0.178                                   0.092                                  0.932                                        0.539                                    0.101

  3--9 cigarettes/day   1.25 (0.88--1.78);\               1.41 (1.02--1.95);\                     1.11 (0.73--1.69);\                    1.01 (0.72--1.41);\                          1.24 (0.91--1.69);\                      0.81 (0.58--1.13);\
                        0.208                             0.035                                   0.620                                  0.968                                        0.166                                    0.210

  ≥10 cigarettes/day    1.21 (0.78--1.88);\               1.51 (1.03--2.22);\                     2.05 (1.15--3.64);\                    0.90 (0.61--1.35);\                          1.02 (0.70--1.49);\                      0.66 (0.44--0.99);\
                        0.381                             0.036                                   0.015                                  0.620                                        0.912                                    0.045
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MS, metabolic syndrome; TAG, triacylglycerides; HDL-C, high-density lipoprotein-cholesterol; BP, blood pressure. †According to IDF and AHA/NHLBI-ISO 2009 ^[@ref-27]^. ‡According to The Maracaibo City Metabolic Syndrome Study ^[@ref-28]^: WC ≥98cm for men; ≥91cm for women.

###### 

Click here for additional data file.

Copyright: © 2019 Bermudez V et al.

2019

Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).

Discussion
==========

Cigarettes are composed of more than 1000 toxic and carcinogenic elements. Nicotine is the main alkaloid in tobacco; it constitutes 1.5% of the commercial cigarette weight and 95% of the total alkaloids present ^[@ref-29]^. Despite its effects, cigarette smoking has spread all over the globe, becoming a leading cause of chronic and degenerative pathologies. In Latin America, its use has markedly increased since 1950, and is now considered the second most common cardiovascular risk factor, following high blood pressure ^[@ref-30]^. This has led to an increase in cancer deaths and a drop in life expectation of 2--6 years ^[@ref-31]^. In Maracaibo, high prevalence of cigarette smoking and MS has been observed, which may suggest an existing relationship between these variables ^[@ref-6],\ [@ref-32]^. The main finding in this report is the relationship between cigarette smoking and metabolic syndrome, being associated specially with low high-density lipoprotein-cholesterol, increased abdominal circumference and elevated triacylglyceride levels.

In this study, MS prevalence in current smokers was 42.1% in both genders and a greater probability of having MS than in nonsmokers was observed. Kang and Song in the Korea National Health and Nutrition Examination Survey (KHANES) reported similar results with a cross-sectional study with 11559 subjects. They evaluated smoking habit by looking for nicotine in urine samples; a greater risk for developing MS was observed in those subjects ^[@ref-33]^. Likewise, Slagter *et al.* ^[@ref-11]^ conducted a study in the Netherlands which included 59,467 subjects from both sexes. In that study, a higher prevalence of MS was observed in smokers (a dose-dependent relationship), and increased the risk of MS depended neither on BMI nor gender.

Sun *et al.* ^[@ref-8]^ conducted a meta-analysis from multiple cohort studies and included 13 articles. In total, 56,691 subjects and 8688 cases from Asia, Europe and North America were included. They found that cigarette smoking actively increases the risk of having MS. The effects of smoking on the cardiovascular system could be caused by increased action of nicotinic receptors. Activation of nicotinic receptor could promote the release of neutransmitters and hormones such as vasopressin, CRH, ACTH, growth hormone, dopamine, serotonin, glutamate and GABA in the central nervous system, acetylcholine in the peripheral nervous system, and catecholamine and cortisol from the adrenal glands. All of these molecules affect metabolism and appetite regulation ^[@ref-34]^.

The CKB cohort study ^[@ref-35]^ included 487,527 adult subjects and reported that regular cigarette smoking was associated with a decrease in BMI and an increase in abdominal circumference in both men and women (they used an adjusted model for BMI). Similar results were reported from the FINRISK study ^[@ref-36]^, which included 5817 Finnish adults; greater abdominal circumference was observed in overweight and obese women who smoke. Clair *et al.* ^[@ref-37]^, in a cross-sectional study that included 6123 adult Caucasians from Switzerland, reported that both sexes had an increased risk of obesity according to the number of cigarettes they smoke per day. These results resemble those from the present study, where cigarette smoking was associated with increased abdominal obesity. This epidemiological behavior could be explained by the recent hypothesis of the association between cigarette smoking and a decrease in body weight, using the CHRNA3 genetic variant (rs1051730); establishing that smoking does not affect body fat distribution and the increase in localized visceral fat and in abdominal obesity are due to high cortisol plasma levels and insulin resistance, respectively ^[@ref-38]--\ [@ref-40]^.

In this study, cigarette smoking represents a risk factor for having high TAG levels. Similar behavior was seen in the ICMR-INDIAB cross-sectional study ^[@ref-41]^ of 16,607 adult individuals, which showed a positive correlation between high TAG levels and smoking. Ueyama *et al.* ^[@ref-42]^ reported there was a positive association between smoking and high TAG levels in a study of 5959 Japanese individuals. This phenomenon could be explained by the fact that stimulation of the sympathetic nervous system produces the release of insulin antagonists. These antagonists, such as cortisol and growth hormone, increase lipolysis, leading to an elevation of free fatty acids in the blood ^[@ref-8],\ [@ref-40]^.

Low HDL-C levels were observed more frequent in smokers than nonsmokers in our study. Sun *et al.* ^[@ref-43]^, in a cross-sectional study of 11,956 Chinese individuals, reported similar results by showing that current smokers had an increased risk of having low HDL-C levels. Takata *et al.* ^[@ref-44]^, showed that in 32 individuals who were participating in an anti-smoking program using varenicline or transdermal nicotine patches, HDL-C levels, apolipoprotein AI and HDL subfractions did not change significantly according to therapeutic strategy used. In the same study, cholesterol efflux capacity and HDL inflammatory index improved significantly with the anti-smoking program (baseline cholesterol efflux capacity: 14.15±2.46% vs after smoking cessation cholesterol efflux capacity: 14.83±2.35%; *p*=0.01; baseline HDL inflammatory index: 1.13±0.31 vs after smoking cessation HDL inflammatory index: 0.98±0.18 %; *p*=0.01).

The inverse relationship between current cigarette smoking and high blood pressure observed in the present study is noteworthy. However, three decades ago cigarette smoking was globally reported as acutely increasing blood pressure, heart frequency and myocardial contractility ^[@ref-45]^. This was thought to be caused by increased nicotinic activity on the sympathetic nervous system. Despite this, epidemiological evidence could not confirm the role of cigarette smoking in the development of elevated blood pressure ^[@ref-46]^. On the other hand, diverse evidence suggests an inverse relationship between these factors. Kaneko *et al.* ^[@ref-47]^, in a recent study of 1297 Japanese individuals without any history of high blood pressure, showed that cigarette smoking appeared to be a "protective" factor against blood pressure elevation. Onat *et al.* ^[@ref-48]^ observed a similar pattern in a Turkish population. The inverse association between blood pressure and smoking habit could be related to the cigarette effect on weight loss, since obesity is associated with a high incidence of high blood pressure; explaining the rebound effect on blood pressure in obese subjects who stop smoking ^[@ref-48]^; however, this study evidenced that smokers presented with more abdominal obesity than nonsmokers. Another theory to explain this behavior suggests that smokers show less response to psychological stress: many of them report a decrease in anxiety and stress when smoking a cigarette ^[@ref-49]^. This may come from modifications to adrenal and cardiovascular responses to external stimuli caused by cigarette smoking; thus, stopping smoking would increase blood pressure ^[@ref-50]^.

Leone ^[@ref-51]^ reports a two-phase effect of cigarette smoking on arterial pressure: the first phase, without a determined duration, when there is a decrease in blood pressure; and the second phase, when the smoker develops elevated blood pressure from the toxic effects of carbon monoxide ^[@ref-51]^. This finding shows the importance in chronologically assessing smoking habit duration. Despite this, smoking does not benefit to cardiovascular health, but increases the risk of cardiovascular disease, especially in men ^[@ref-48]^. These are not the only contradictory findings in relation to tobacco use and the presence of hypertension, recently Gonzalez *et al*. ^[@ref-52]^ reported in a population from The Andes region of Venezuela, an association between the \"chimó\" consumption (a smokeless tobacco preparation) and lower frequency of hypertension, suggesting that the occurrence of masked hypertension in tobacco users as a possible explanation-an issue that is highly probable given the prejudices known to patients when using these products. Therefore, analyses with ABMP are necessary to assess the effect of tobacco on blood pressure throughout the day.

Similarly, with the assessment of smoking intensity according to number of cigarettes per day, a direct relationship was found between the number of cigarettes smoked and an increased risk of high serum TAG levels and abdominal obesity, and an inverse relationship with hypertension; this was seen especially in heavy smokers (≥10 cigarette daily). In this sense, in a study performed by Chen *et al.* ^[@ref-10]^, 1146 individuals showed a significant dose-response relationship between the number of cigarettes per day and high TAG levels. Data analysis from the KHANES study revealed an increased risk of obesity and central obesity with an increase in smoking habit intensity ^[@ref-53]^. This relationship could be caused by the dose-dependent effect of nicotine on fatty acid metabolism and catecholamine release; also inducing increase in lipolysis, free fatty acids, VLDL, LDL levels, and visceral adipose tissue independent of weight gain or loss ^[@ref-54]^.

In the present study, former smokers did not exhibit an increased risk of developing MS or its components when compared with non-smokers. Similar results were reported in Korea by Oh *et al.* ^[@ref-55]^. The benefits to cardiovascular health from stopping cigarette smoking seem to depend on the following variables: first, the time since the subject stopped; and second, the length of time for which he/she was smoking and the quantity of cigarettes. A previous study showed that smoking 20 cigarettes daily increased the risk of developing MS for the next 10 years, whereas smoking 40 cigarettes daily increased the risk for the next 20 years ^[@ref-56]^. This is why in the Maracaibo population it is necessary to conduct a cohort study on subjects who stopped smoking to evaluate the long term effects on cardiometabolic health.

Regarding the limitations of this study, its cross-sectional design makes it incapable of determining causality; it is also influenced by the subjectivity of its participants regarding the intensity and duration of their smoking habit. All of this should be considered in future studies.

In conclusion, the present study showed that smoking in our population represent a related factor with MS, and is individually associated with low HDL-C levels, increased abdominal circumference and high TAG levels. Former smokers did not show any increase in risk of present MS relative to non-smokers; despite this, future research studies should be conducted to evaluate how stopping cigarette smoking decreases cardiometabolic risk. Prevention measures focused on patients who smoke, especially anti-smoking counseling from medical personnel, could help to decrease any cigarette cardiometabolic consequences in the Maracaibo City population.

Data availability
=================

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2019 Bermudez V et al.

Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication). <http://creativecommons.org/publicdomain/zero/1.0/>

**Dataset 1. Cigarette smoking and MS MMSPS dataset.** DOI: [10.5256/f1000research.14571.d201851](http://dx.doi.org/10.5256/f1000research.14571.d201851) ^[@ref-57]^
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